Royal DSM, a global life sciences and materials sciences company, has made adjustments to its organizational and operating model, including a reduction in headcount of 900 to 1,100, half of which will occur in the Netherlands. Those cuts will be fully implemented by the end of 2017.
Organization changes will result in structural savings of $142 to $170.6 million to be fully achieved by the end of 2017. DSM also will strengthen its management structure by establishing an executive committee, enabling faster strategic alignment and operational execution.
Executive committee members include Feike Sijbesma, CEO/chairman; Geraldine Matchett, CFO; Stephan Tanda, life sciences; Dimitri de Vreeze, materials sciences; Chris Goppelsroeder, nutritional products; Philip Eykerman, strategy and M&A; Rob van Leen, R&D and innovation; and Peter Vrijsen, human resources. The statutory responsibilities of the managing board remain unchanged.